High Lantern Group Adds Drew Holzapfel to New York Office

Brings Global Experience in Healthcare and Product Strategy to Leading Consultancy

Apr 01, 2013, 10:28 ET from High Lantern Group

NEW YORK, April 1, 2013 /PRNewswire/ -- Drew Holzapfel, a senior healthcare executive with more than 15 years of experience in corporate public affairs, sales and marketing across the pharmaceutical and biotechnology industries, has joined High Lantern Group as a Managing Director in the New York office. Holzapfel is an innovator of progressive programs and strategic partnerships to shape healthcare public policy to better meet the needs of patients and their caregivers both in the United States and internationally.

"Drew's skills in strategic communications and coalition building, his unique knowledge of U.S. and international healthcare systems and policy, and his expertise in the pharmaceutical and biotechnology industries will greatly enhance High Lantern Group's work in the areas of health and aging," said Michael W. Hodin, Managing Partner. "Drew will strengthen our existing service offerings and add a new level of insights and strategic thinking for our clients. We are thrilled to add him to our growing team."

Holzapfel joins High Lantern Group from Pfizer, where he most recently served as Director of Global Commercial Development for the company's Alzheimer's program. In this role, he led numerous efforts to advance Alzheimer's and aging issues through development of commercial strategy, advocacy and partnerships with international organizations, nongovernmental organizations, nonprofits and other key stakeholders. Prior to joining Pfizer, Holzapfel managed an external affairs team for a medical device manufacturer, helping steer the company through an initial public offering and the launch of its first product. A former Special Assistant to the Secretary of the U.S. Department of Health and Human Services in the Clinton Administration, he began his career as a political appointee working on communications for a Presidential initiative in the White House.

"High Lantern Group has built a unique niche within the consultancy business, offering great value to clients in the areas of strategic positioning and thought leadership," said Holzapfel. "I am excited to become part of this trailblazing group of professionals and follow my passion for shaping business strategies, institutions and policies to better serve global healthcare needs."

As part of High Lantern Group's New York office, Holzapfel will be responsible for client management and business development in the areas of health and aging. In addition to serving many clients on financial services, consumer business, and travel and tourism, the firm created and manages the Global Coalition on Aging, a consortium of global corporations driving public policy, strategy and business innovation to promote healthy and active aging in light of the 21st century's age-related demographic transformation.

Holzapfel has led the development of ReACT (reactconnection.com), a coalition of Fortune 500 companies seeking to better support employees serving as caregivers, which was launched at the World Economic Forum in 2010. Additionally, he participated in the creation of the CEO Initiative on Alzheimer's Disease, a business coalition focused on improving Alzheimer's research and development, diagnosis and treatment and raising awareness of the disease.

SOURCE High Lantern Group